NRXS
AMEXNeuraxis Inc.
News25/Ratings0
News · 26 weeks39+180%
2026-03-012026-08-23
Mix2090d
- SEC Filings8(40%)
- Insider8(40%)
- Earnings2(10%)
- Other2(10%)
Latest news
25 items- SECNeuraxis Inc. filed SEC Form 8-K: Leadership Update, Other Events8-K - Neuraxis, INC (0001933567) (Filer)
- INSIDERDirector Watkins Bradley Mitchell was granted 26,073 shares, increasing direct ownership by 56% to 72,408 units (SEC Form 4)4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERSEC Form 4 filed by CMO, SVP Science & Tech Miranda Adrian4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERDirector Keyser Jane Elizabeth was granted 26,073 shares, increasing direct ownership by 56% to 72,408 units (SEC Form 4)4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Henrichs Timothy Robert4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERDirector Ferge Kristin A was granted 31,134 shares, increasing direct ownership by 87% to 67,072 units (SEC Form 4)4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERSEC Form 4 filed by CRO, CCO, CPO Carrico Thomas Joeseph4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Carrico Brian Allen4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERDirector Aharon Gil was granted 86,224 shares, increasing direct ownership by 136% to 80,058 units (SEC Form 4)4 - Neuraxis, INC (0001933567) (Issuer)
- PRNeurAxis Reports Record Second Quarter 2026 Financial Results Driven by 116% Year Over Year Revenue GrowthCARMEL, Ind., Aug. 11, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the second quarter period ended June 30, 2026. 2Q26 Financial Highlights Revenues increased 116% year over year to $1.9M, reflecting continued growth from the Category I CPT code assignment for Percutaneous Electric Nerve Field Stimulation (PENFS) effective January 1, 2026, substantially increasing payer coverage.Expanded gross margin by 230 basis points as significantly more devices were sold at full reimbursement price r
- SECSEC Form 10-Q filed by Neuraxis Inc.10-Q - Neuraxis, INC (0001933567) (Filer)
- PRNeurAxis Expands Payer Coverage with New PoliciesCARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced additional medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing over 500,000 covered lives. This coverage will expand incremental access to IB-Stim treatment for beneficiaries in the Mid-Atlantic region. "As we continue to make meaningful progress with the nation's largest payers, adding coverage from regional health plans like these broadens patient access and strengthens our reimbursement n
- SECSEC Form EFFECT filed by Neuraxis Inc.EFFECT - Neuraxis, INC (0001933567) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Neuraxis Inc.SCHEDULE 13G/A - Neuraxis, INC (0001933567) (Subject)
- SECAmendment: SEC Form S-3/A filed by Neuraxis Inc.S-3/A - Neuraxis, INC (0001933567) (Filer)
- PRNeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026CARMEL, Ind., July 28, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its second quarter period ended June 30, 2026, on Tuesday, August 11, 2026, before market open. The Company has scheduled a conference call for the same day, Tuesday, August 11, 2026, at 9:00 am ET to review the results. Conference Call Details Date and Time: Tuesday, August 11, 2026, at 9:00am ET Toll Free: 1-877-270-2148 (U.S. and Canada toll-free) International: 1-412-317-6060Webcast: https://ap
- SECSEC Form S-3 filed by Neuraxis Inc.S-3 - Neuraxis, INC (0001933567) (Filer)
- SECSEC Form S-8 filed by Neuraxis Inc.S-8 - Neuraxis, INC (0001933567) (Filer)
- SECNeuraxis Inc. filed SEC Form 8-K: Other Events8-K - Neuraxis, INC (0001933567) (Filer)
- SECNeuraxis Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Neuraxis, INC (0001933567) (Filer)
- PRNeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue GrowthCARMEL, Ind., May 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter period ended March 31, 2026. 1Q26 Financial Highlights Revenues increased 80% year over year to $1.6M, reflecting the AMA Category I CPT® code assignment for Percutaneous Electrical Nerve Field Stimulation (PENFS) effective January 1, 2026, substantially increasing payor coverage.Expanded gross margin by 200 basis points and improved operating loss by 24% year over year as more IB-Stim® devices were sold a
- SECSEC Form 10-Q filed by Neuraxis Inc.10-Q - Neuraxis, INC (0001933567) (Filer)
- PRNeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026CARMEL, Ind., May 05, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its first quarter 2026, for the period ended March 31, 2026, on Tuesday, May 12, 2026, before market open. The Company has scheduled a conference call for the same day, Tuesday, May 12, 2026, at 9:00 am ET to review the results. Conference Call Details Date and Time: Tuesday, May 12, 2026, at 9:00am ET Toll Free: 1-877-270-2148 (U.S. and Canada toll-free) International: 1-412-317-6060Webcast: https:
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Neuraxis Inc.SCHEDULE 13G/A - Neuraxis, INC (0001933567) (Subject)
- INSIDERDirector Aharon Gil was granted 234,221 shares, increasing direct ownership by 57% to 33,902 units (SEC Form 4)4 - Neuraxis, INC (0001933567) (Issuer)
NRXS FAQ
5 questionsWhere does NRXS stock trade?
Neuraxis Inc. (NRXS) is listed on AMEX.What sector and industry is NRXS in?
Neuraxis Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.When did Neuraxis Inc. go public?
Neuraxis Inc. (NRXS) completed its IPO in 2023.What companies are similar to NRXS?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare NRXS side-by-side with any of them on Quantisnow.How can I track NRXS on Quantisnow?
Quantisnow aggregates Neuraxis Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NRXS to receive live email and push alerts on every new disclosure.